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ABSTRACT
Objective: To identify the mutation in the rpoB gene of Mycobacterium tuberculosis (MTB), using by sequencing method from pulmonary specimens 
of presumptive TB patients belonging to the districts of Tamil Nadu.
Methods: A total of 8697 clinical specimens of presumptive MTB patients were collected from various districts of Tamil Nadu. Smear microscopy was 
performed by light emitting diode fluorescent microscopy and all the smear positive samples were tested using line probe assay (LPA) to detect the 
percentage of drug resistance pattern and to identify the missing mutation in LPA by the sequencing method.
Results: Among 4897 smear positives subjected to LPA method; 407 (8.3%) MTB was not detected and 16 (0.3%) showed invalid result; 4473 (91.4%) 
strains showed MTB positive; 3695 (82.6%) were sensitive for both rifampicin (RIF) and isoniazid (INH) drugs; 502 (11.2%) were resistance for INH; 
73 (1.6%) resistant for RIF; 203 (4.5%) were resistance for RIF and INH. Totally, 52 (1.2%) strains results cannot be confirmed by LPA and reported 
as sensitive for RIF, because of the faint and the missing bands in both wild type and mutation. These strains were sequenced and 39 (75%) strains 
showed resistant to RIF.
Conclusion: Hence LPA may be the molecular technology for the rapid, feasible and reliable method for the detection of multidrug resistant mutation 
but few confusion bands cannot be reported as resistance, which should be confirmed by either conventional phenotypic drug susceptibility testing 
or by sequencing method.
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INTRODUCTION
In 2013, more than 9 million people fell ill with tuberculosis (TB) and 
4,80,000 people developed multidrug-resistant TB (MDR-TB) globally 
and there were an estimated 2,10,000 deaths from MDR-TB [1]. In 
worldwide, the TB disease remains the most dangerous infectious 
diseases. Providing treatment and control of TB is more complicated 
due to emergence of drug resistant even MDR strains, MDR-TB can be 
defined as resistant to both isoniazid (INH) and rifampin (RIF) with or 
without other anti-TB drugs [2]. Around 500 new smear-positive MDR-
TB cases were estimated to occur per year in the country [3].
Conventional culture and drug susceptibility testing (C & DST) by solid 
or liquid is a slow process which may take 2-4 months, during this 
time a patient is often treated according to the standard regimen for 
drug-susceptible TB. This results delay in proper treatment, adversely 
affect the outcome of the treatment and transmission of the drug 
resistant TB [4]. The financial, infrastructural and human resource 
requirements, widespread implementation of culture-based DST is 
challenging in such settings. The specimen transport and the specimen 
contamination issues may also present further challenges [5], hence 
early diagnosis of TB and rapid detection of RIF resistance is important 
for proper management of drug-resistant TB [6]. Even though major 
efforts are being taken and implemented by the government to increase 
case detection, one-third of new TB cases are still missed due to 
nonavailability of rapid, low-cost, and accurate diagnostic facilities in 
high-TB-burden countries like India. Over the last many years, efforts 
were taken to improve and develop rapid diagnostic tools for diagnosis 
and DST of TB. The World Health Organization (WHO) issued 10 
policy statements for improving diagnosis of TB, including the use of 
commercial and noncommercial DST methods and implementation 
of molecular methods such as the line probe assay (LPA) and Xpert 
Mycobacterium TB (MTB)/RIF assay [7].
In INH-resistant strains, the most common mutations were occurred 
in either the gene (katG) encoding catalase-peroxidase, which is 
required for the activation of prodrug INH, or in the promoter 
region of the inhA, encoding enoyl-acyl reductase, which is involved 
in Mycobacterium cell wall biosynthesis [8,9]. RIF resistance strains 
were serve as a surrogate marker for MDR-TB detection because 
96% RIF-resistant strains are also resistant to INH [10]. Resistance 
in RIF was attributed to mutations within an 81-bp RIF resistance-
determining region (RRDR) of the rpoB gene, corresponding to codons 
507-533 in 96% of RIF resistance strains [11,12]. Mutations outside of 
RRDR were also reported with a frequency of <2% [13]. More than 50 
mutations were characterized within this region by deoxyribonucleic 
acid (DNA) sequencing but only point mutations at codons 526 or 
531 are known to cause high levels of RIF resistance [14]. In contrast, 
mutations in codons 511, 516, 518, 522, and 533 cause low-level 
resistance to RIF. Mutations conferring RIF resistance occur rarely in 
other regions of the rpoB gene [15]. Of the two recently introduced 
molecular diagnostic methods for RIF resistance detection, LPA 
technology is based on reverse hybridization of DNA on the strip, 
when the Xpert MTB/RIF assay is based on real-time polymerase 
chain reaction (PCR). The strip-based DNA hybridization, i.e., the 
genotype MTBDRplus (Hain LifeScience, Nehren, Germany) referred as 
to LPA. Both LPA and Xpert MTB/RIF assays show good performance 
(98% sensitivity) for RIF resistance detection when compared with 
the gold standard phenotypic DST. As per the WHO guidelines, the 
standard turnaround time for reporting the LPA results is 2-3 days, 
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depending on the timings of sample receiving and reporting of the 
result. It is mainly advocated for using with smear-positive samples. 
Where its sensitivity is reported to be 98%. In smear-negative/
culture-positive samples its detection rate is low (72.5-76.9%) [16], 
though its accuracy may vary from region to region due to variation 
in the circulating MTB strains [17]. Recently, the WHO recommended 
the use of molecular LPAs for rapid screening of MDR-TB in low and 
middle income settings [18]. These new assays were developed to 
detect resistance faster using genotype, rather than phenotype. The 
GenoType® MTBDRplus test is a DNA strip assay which uses multiplex 
PCR and amplification and reverse hybridization to identify MTB 
complex and mutations to detect mutations in the inhA, katG, and 
genes rpoB genes that confer RIF and INH resistance [19].
LPAs use PCR, LPA is performed directly from acid-fast bacilli (AFB) 
smear-positive sputum, or from culture isolates, and provide results 
in 1-2 days. A recent systematic review concludes that LPA are highly 
sensitive and specific for the detection of RIF resistance (≥97% 
and ≥99%) and INH resistance (≥90% and ≥99%) on culture isolates 
and smear-positive sputum. Overall agreement with conventional DST 
for detection of MDR-TB was 99% [20].
METHODS
Ethics and settings
This laboratory is accredited as an Intermediate Reference Laboratory 
(IRL) for LPA testing by Revised National TB Control Programme 
(RNTCP), India, and certified by the National Reference Laboratory 
(NRL), National Institute of Research in TB, Chennai. Since the 
observations were made as a part of national TB control program, a 
separate ethics clearance was not required [21].
Specimens and the study population
A total of 8697 specimens of presumptive MDR-TB cases were received 
for C & DST from the district TB center (DTC) of Tamil Nadu from January 
to December 2015. These specimens were collected and packed with 
ice gel pack and transported through courier as per standard operating 
procedure from DTC’s to the laboratory. The smear microscopy was 
performed by fluorescent microscopy method (Auromine-O)-light 
emitting diode FM [22]. Based on smear microscopy results, the smear 
positive specimens 4897 were subjected to LPA genotypic method. 
The GenoType® MTBDRplus assay (LPA) (Hain LifeScience GmbH, 
Nehren, Germany) was carried out according to the manufacturer’s 
instructions [23].
Laboratory work-up of sputum specimens
Sample processing
All sputum samples were processed using the N-acetyl-L-cysteine-
sodium citrate-NaOH method and neutralized with phosphate buffer 
solution pH 6.8. [24]. Samples were decontaminated by the following 
centrifugation, and these sediments were resuspended for 2 ml of 
phosphate buffer solution. Aliquots were prepared from the processed 
sample per quantity of the original sample.
LPA
The LPA was performed according to the manufacturer’s protocol [25]. 
The test is based on DNA strip technology and has three steps: DNA 
extraction, multiplex PCR amplification, and reverse hybridization 
(Fig. 1), all the three steps were performed as per the WHO 
recommendations as follows (Fig. 2) [26].
DNA extraction
The LPA diagnostic technique is based on the PCR amplification of 
specific regions of DNA. DNA must, therefore, be extracted from the 
specimen under investigation to make a genotypic diagnosis of the drug 
susceptibility pattern. The extraction of the DNA from the AFB in the 
specimen is done by chemical denaturation after the partial cell lyses 
during the heat-killing step.
DNA amplification
Target DNA was amplified and it is the template to the amplification. 
Primers (short oligonucleotides of between 18 and 26 base pairs) that 
will recognize their corresponding sequence on the single stranded 
DNA and initiate the reaction, and the DNA precursors (the four 
deoxynucleoside triphosphates, dATP, dCTP, dGTP, and dTTP) these are 
used as building blocks for the elongation of the single stranded DNA. 
A thermo stable Thermus aquaticus DNA polymerase (Hot Start Taq) 
which will elongate the DNA molecule by facilitating the incorporation 
of the free nucleotides onto the end of the primer, according to the 
complementary base on the single stranded target DNA.
These reactions are fundamental in ensuring that sufficient DNA is 
amplified and will be easily detected in the hybridization process, after 
30 cycles of amplification, the DNA products will be in the order of 230, 
with sufficient product to be easily visualized as a distinct band when 
bound to probes on the LPA strip.
Hybridization
Hybridization was performed by automated GT blot 48. This chemical 
denaturation of the amplified products were hybridization of the 
single-stranded-biotin-labeled amplicons to membrane-bound probes 
and stringent washing of the nonspecifically bound amplicons with 
the addition of a streptavidin/alkaline phosphatase (AP) conjugate. 
The banding patterns are produced when the substrate (hydrogen 
peroxide) reacts with the AP, these turns and visualized the bound 
amplicons purplish-brown (Fig. 3) [27].
Sequencing
Few strains results cannot be confirmed by LPA and reported as 
sensitive for RIF, because of the faint and the missing bands in both 
wild type and mutation. These strains were sequenced to identify the 
changes in the amino acid sequence and mutations were detected 
in rpoB gene of MTB for RIF resistance.
RESULTS
A total of 4896 AFB smear positive pulmonary specimens were tested 
with LPA method. Out of 4896 samples 407 (8.3%) samples were MTB 
not detected and 16 (0.3%) invalid results on the LPA. Of the remaining 
4473 samples, 3695 (82.6%) were susceptible for the both RIF and 
INH, 203 (4.5%) had MDR, 502 (11.2%) showed INH mono resistance, 
and 73 (1.6%) shows RIF mono resistance as shown in Table 1. Among 
4473 MTB detected by LPA method, 52 (1.2%) were reported as 
sensitive with the faint and missing band in WT8 and also in MUT 3 but, 
out of these 52 specimens, 39 (75%) specimens showed resistant by 
sequencing method Tables 1 and 2.
DISCUSSION
Rapid diagnosis for the resistant associated with the drug resistant 
strains due to the mutation is a major challenge for the successful 
treatment of the drug resistance TB. At present available methods 
such has LPA method (GenoType MTBDRplus), which offers limited 
detection capabilities, particularly when novel or uncommon amino 
acid substitutions and in the silent mutation due to changes within the 
known drug resistance regions or even in the undiscovered amino acid 
mutation impact drug resistance [28]. Hence, the sequence for doubtful 
and the faint bands strains to identify the changes or the mutations in 
the genes to diagnose the drug resistance TB even rapidly are done in 
this study.
In this study, the drug resistant TB is about 273 (6.2%), this is 
comparatively less than other study of 2.3% [29], LPAs are currently 
validated only for using directly from smear-positive specimens, 
although the reasonable performance in a small sample of smear-
negative specimens was demonstrated by Barnard and Somoskovi. 
Although smear-positive TB cases are the most infectious [30], as part 
of its role in the development and evaluation process of new diagnostic 
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Fig. 1: Illustration of the DNA-strip technology by Hain Life Science. The GenoType®. MTBDRplus molecular line probe assay is divided 
into three procedures: (1) DNA extraction from NaOH-N-acetyl-L-cysteine-sodium citrate decontaminated smear positive specimens or 
from cultured isolates (solid or liquid media), (2) a multiplex polymerase chain reaction amplification, and (3) the reverse hybridization 
(including detection and evaluation)
Fig. 2: An illustration of the work flow for the ideal physical 
design layout (4 room polymerase chain reaction [PCR] facility) 
and a basic (3 room PCR facility). Reagent preparation in the pre-
amplification room must always be performed before any other 
procedure can be done
Fig. 3: (a) The bands (except CC) should be compared to the AC 
control band for density, (b) The TUB zone is negative, the tested 
bacteria does not belong to the M. tuberculosis complex and the 
presence or absence of any other bands (except CC and AC) cannot 
be considered for evaluation, (c) if the locus control zones are 
negative, the respective mutation-specific positive bands cannot 
be considered for evaluation, (d) absence of the signal with wild 
type probes may predict resistance, while positive hybridization 
signal with a mutation-specific capture probe (for common 
mutations only) may predict the resistance, (e) presence of the 
rare mutations may only be indicated by the lack of hybridization 
with one or more wild type probes
technologies, FIND negotiated with the manufacturing partner to 
obtain significant price reductions for equipment and reagents for LPA 
testing for the public health sector in high burden countries to facilitate 
widespread access to the WHO-approved technologies [46].
The MTB rpoB gene encodes the 1178 amino acid beta subunit for a 
DNA-dependent RNA polymerase enzyme, the mutations within an 
81 base pair called “Core region” of the rpoB gene are responsible for 
approximately 95% of the RIF resistance in MTB strains [31]. It is found 
that about most of the resistant strains harbor mutations in 531 codon 
of the rpoB region. As reported widely elsewhere, RIF resistance was 
highly associated with mutation in the 81 base pair region of the rpoB 
gene [32,33].
The MTBDRplus assay is easy to perform and it has the capability 
for the rapid detection of RIF and INH-resistant MTB [34-37], the 
rarity of RIF-resistance-associated mutations in codons other than 
the rpoB 81-bp hot spot region and the rarity of silent mutations in 
the hot spot region are responsible for the high rate of detection of 
RIF resistance by investigation of this region [37-40]. In this study, 
the S531L/W mutation in rpoB is the most frequent 32 of 52 strains 
(61.5%), followed by mutations in codon 526, 7 of 52 strains (13.5%) 
as shown in Table 2. This is comparable to the frequencies reported in 
other studies [37], even though the distribution can also vary in few 
settings [47].
The detection of mutations in the hot spot 81-bp region of the rpoB 
gene was analyzed and compared with the sequence results. The 
confusion results such as the faint band in 531 codon WT8 or missing 
bands in both WT8 and MUT3 were selected and sequenced to 
identify the changes in amino acid sequence and nucleotide changes. 
When the WT8 band is weaker than that of AC and the corresponding 
mutation band rpoB MUT3 is not developed and it is considered as 
sensitive as shown in the Table 2 [41]. In this study, three of these 
mutations, yielding amino acid substitutions at positions 531 
(Ser→Leu/Trp) and in 526 (His→Tyr/Asp/Arg/Leu) (Fig. 4) and also 
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it is found that, out of 52 strains reported as sensitive the sequence 
results show amino acid changes in 531 codon, i.e., Ser531Leu for 
30 strains and Ser531Trp for 2 strains, interestingly identified 
that additional changes in 526 codon, i.e., His526Tyr for 1 strain, 
His526Asp for 3 strains, His526Arp for 1 strain, and His526Leu for 
2 strain, since both mutant and wild-type bands are absent (Table 2). 
The Ser531Trp mutation occurs less frequently than Ser531Leu, 
similarly uncommon amino acid substitution that are missed by LPA 
also is identified at position 526 (Table 2). However these sequencing 
reveals that 39 of 52 isolates are resistant and LPA is shown as the 
faint band or absent in wild type and missing of corresponding 
mutation band (Fig. 4).
When the isolate is RIF resistant, it is more likely that it is also INH 
resistant, thus making RIF resistance a surrogate marker for the 
identification of MDR-TB [40]. It is also well established that isolates 
harboring mutations between codons 526 and 531 shows high-level 
resistance to RIF and that these genetic markers carry very high 
accuracy in RIF resistance detection [42-45]. Molecular technologies 
like LPA is the most promising technology to detect these mutations 
but the recommendation in these cases is either to control the result by 
DNA sequencing or confirm the result by the conventional DST.
CONCLUSION
The analysis of 52 strains which was reported as sensitive due to the 
confusion, i.e., the faint band or the missing band in WT8 and also 
missing of MUT 3 band. In this 52 strains, the amino acid changes were 
observed in 39 strains and it may be reported as RIF resistant and for 
these patients, the treatment may be provided and the transmission of 
the drug resistant TB also will be prevented by diagnosing these kind 
of samples by sequencing method rather than providing false negative 
report because of the confusion.
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